Key Findings Disparities in outcomes across different patient groups defined based on race, ethnicity, gender, age, socio-economic factors, and other factors are significant and can be attributed to many intersectional drivers related to healthcare awareness, access and delivery, in addition to factors related to genetics While access and delivery of care are major factors driving disparities in outcomes, a comprehensive clinical development program that addresses diversity and ranges from pre-clinical and exploratory studies through randomized confirmatory trials for safety and efficacy through to post-approval real-world studies can advance understanding of optimal patient care, expand access to care, bring earlier insights, and accelerate innovation Stakeholders in the U.S
inhibition by DFO or ferrostatin-1 confirms ferroptosis dependence (245, 246)
For many patients, this combination helps reduce abdominal discomfort, improve nutrient absorption, and maintain remission longer between flare-ups
10.1080/0886022X.2021.1997764 24 ChenJ.DuL.LiJ.SongH
Pharmacol Rev (2023) 75:30927